1. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis 
William R. Lumry, MD 
Journal of Allergy and Clinical Immunology 
Volume 104, Issue 4, Pages s150-s159 (October 1999)
DOI: /S (99)
Copyright © 1999 Mosby, Inc. Terms and Conditions

2. Fig. 1
Mometasone furoate nasal spray (MFNS) compared with beclomethasone dipropionate (BDP) in seasonal allergic rhinitis. Percentage of patients with no or mild symptoms by physician evaluation. Age ≥18 years. Asterisk, P < .05 compared with placebo vehicle control. NS, Not significant. (Adapted with permission from Hebert JR, Nolop K, Lutsky BN. Once-daily mometasone furoate aqueous nasal spray [Nasonex™] in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51: ©1996 Munksgaard International Publishers Ltd., Copenhagen, Denmark.)
Journal of Allergy and Clinical Immunology  , s150-s159DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions

3. Fig. 2
Mometasone furoate nasal spray (MFNS) compared with fluticasone propionate in the treatment of perennial allergic rhinitis after 12 weeks of topical treatment. Percentage of patients with perennial rhinitis with complete or marked symptom relief after 12 weeks of treatment with mometasone furoate nasal spray (200 mg/day), fluticasone propionate (200 mg/day), or placebo. N = 550, age 12 to 77 years. (From Day J, Nolop K, Lutsky BN, I Study Group. Comparison of once-daily treatment with mometasone furoate [Nasonex™] and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis [abstract 1792]. J Allergy Clin Immunol 1997;99:S441.)
Journal of Allergy and Clinical Immunology  , s150-s159DOI: ( /S (99) )
Copyright © 1999 Mosby, Inc. Terms and Conditions